News: ACADIA Pharmaceuticals Inc (ACAD.O)
14.25USD
20 May 2013
$0.98 (+7.39%)
$13.27
$13.46
$14.75
$13.40
5,516,317
3,734,067
$14.75
$1.29
Thu, Apr 11 2013
Acadia says data from Parkinson's trial enough to file for approval
- Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, and that it would not need to conduct an additional trial as planned earlier.
BRIEF-ACADIA Pharma up in premarket after phase III pimavanserin study data
NEW YORK, March 21 - ACADIA Pharmaceuticals Inc : * Pharma up 6.5 percent to $7.08 in premarket after phase III pimavanserin study data
UPDATE 1-Acadia antipsychotic for Parkinson's succeeds in trial
* Achieves antipsychotic effect without loss of motor function
- Too Many Questions Make This Thursday Mover a Sell
- 5 of Last Week's Biggest Winners
- This Stock Should Get Better in the Long Run
- 2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Play
- ACADIA Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
- The Fool Looks Ahead
Press Releases
- ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
- ACADIA Pharmaceuticals Prices Public Offering of Common Stock
- ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Faruqi & Faruqi, LLP Launches An Investigation Against ACADIA Pharmaceuticals Inc. (ACAD) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
- ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results
- ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013
- ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
- GOFF Corporation Shares Halt The Slide Looking For Follow Through- Top Five Small Cap Stocks Ahead Of The Bell: Lyon Williams, Acadia Pharmaceutical, Fannie Mae, AMR Corporation
- Retailers Push Stocks Higher and Pfizer Inc. hits a new 52-Week High
- ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
